Search
for
Sort by
Research 601–630 of 1000+
- Selective JAK 1 inhibition with upadacitinib as a potential treatment for coexistent severe atopic dermatitis and alopecia areata
- Hypohidrotic Ectodermal Dysplasia with c.28delG Mutation in Ectodysplasin A Gene and Severe Atopic Dermatitis Treated Successfully with Tofacitinib
- Exhaustive analysis of scalp hair regression: subjective and objective perception from initial hair loss to severe miniaturisation and drug-induced regrowth
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
- COVID-19 vaccination related exacerbations of hair loss in patients with moderate-to-severe alopecia areata on systemic therapy
- Highly Efficient Rinse-Off/Leave-On Scalp Care Treatments to Reduce Moderate to Severe Dandruff
- COMPARISON OF EFFICACY OF BARICITINIB VERSUS METHOTREXATE THERAPY IN THE TREATMENT OF SEVERE ALOPECIA AREATA
- Identification of two additional novel mutations in the AR gene associated with severe forms of androgen insensitivity syndrome
- 605 Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
- 77015 Subgroup Analysis of Efficacy of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata From the UP-AA Phase 3 Program
- 74582 Early improvement in scalp hair regrowth with deuruxolitinib in patients with severe alopecia areata: Pooled analysis of the THRIVE-AA1 and THRIVE-AA2 Phase 3 trials
- Adverse effects of baricitinib in comparison to methotrexate in the treatment of severe alopecia areata
- P46 PSYCHOMETRIC PERFORMANCE OF EQ-5D-5L INDEX IN ADULTS AND ADOLESCENTS WITH SEVERE ALOPECIA AREATA: EVIDENCE FROM PHASE III TRIAL DATA
- Cost‐Effectiveness Analysis of Ritlecitinib Compared With No Treatment in Patients With Severe Alopecia Areata in Japan
- Comprehensive single-cell transcriptomic profiling of the scalp from patients with moderate-to-severe alopecia areata
- Analysis of the Current Status of Acute Postoperative Pain and Influencing Factors of Moderate to Severe Pain in Adult Patients Undergoing Ophthalmic Surgery Under General Anesthesia
- Safety and Efficacy of Mesotherapy with Placenta Polypeptide Injection for Moderate-to-Severe Sensitive Skin: A Multicenter, Randomized, Controlled Trial
- Tissue Retinol‐Binding Protein 4 Expression and Its Genetic Variants (rs3758539) in Patients With Severe and Treatment‐Refractory Alopecia Areata: Association With Response to Baricitinib
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- Efficacy of Fire Needle Therapy Combined with Doxycycline Hydrochloride in the Management of Moderate-to-Severe Acne Vulgaris: A Randomized Controlled Trial
- Atypical presentation of Acrodermatitis enteropathica in a child: later onset with life-threatening severe extensive dermatitis and septic shock
- RETRACTION: Observing the Clinical Efficacy of Combined Serum Microneedle Therapy for Moderate to Severe Androgenetic Alopecia in Scalp Repair
- Response to Li et al.’s “Therapeutic efficacy of platelet-rich plasma combining with microneedling and topical minoxidil in refractory severe androgenic alopecia”
- Trichoscopic evaluation in oral tofacitinib and oral betamethasone in the treatment of moderate to severe alopecia areata
- Therapeutic Efficacy of Platelet-Rich Plasma Combining with Microneedling and Topical Minoxidil in Refractory Severe Androgenic Alopecia
- 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
- Observing the clinical efficacy of combined serum microneedle therapy for moderate to severe androgenetic alopecia in scalp repair
- Clinical Benefits of Baricitinib Therapy According to Scalp Hair Regrowth in Patients with Severe Alopecia Areata
- 42146 Concurrent improvement in scalp hair and eyebrow or eyelash regrowth in patients with severe alopecia areata treated with baricitinib
- 43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry